Background: The treatment efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer is unclear. Methods: We defined refractory relapse as treatment-free interval <90 days and poor-risk as Eastern Cooperative Oncology Group Performance Status ≥2. We retrospectively examined the medical record data of patients who were treated at our hospital between September 2002 and December 2014. Results: Twenty-three poor-risk patients with refractory-relapsed small-cell lung cancer were treated in our hospital. The characteristics of patients at the time of first-line treatment were as follows: median age (range) 71 (57-83) years; male 74%; extensive disease 96%; proportion of patients with PS 0 or 1 and those with 2-4 was 43 and 57%, respectively; median treatment-free interval 26 days. Amrubicin was the most commonly used drug and was administered in 15 patients (65%). The overall response rate of all patients was 22%. Median progression-free survival and overall survival was 2.2 and 3.7 months, respectively. Among patients treated with amrubicin, overall response rate was 13%, median progression-free survival was 2.2 months, and median overall survival was 3.9 months. The most common grade 3 or worse adverse events were hematologic toxicities, including leukopenia (66%), neutropenia (69%), thrombocytopenia (9%) and anemia (22%). Febrile neutropenia was observed in two patients (9%). Conclusions: Second-line chemotherapy might have poor efficacy to poor-risk patients with refractory-relapsed small-cell lung cancer.
Introduction
Lung cancer is the most common cause of cancer-related death. Small-cell lung cancer (SCLC) is one of the major histological types of lung cancer and is strongly associated with smoking. Due to changes in smoking habits, the incidence of SCLC has declined in recent years. However, SCLC still accounts for approximately 12% of lung cancers (1) . Although SCLC is highly sensitive to first-line treatment, about 80% of limited-disease patients and almost all patients with extended disease will develop disease relapse or progression (2) . Without second-line chemotherapy, the prognosis of relapsed SCLC patients is poor and median survival time (MST) is 2-4 months (3) .
The efficacy of second-line chemotherapy is influenced by the length of the treatment-free interval (TFI), which is the time from the end of the first-line treatment to relapse. Patients with relapsed SCLC are conventionally separated into sensitive relapse and refractory relapse by TFI (1) . In previous reports, patients with refractoryrelapsed SCLC had a worse response and survival outcomes than those with sensitive relapsed SCLC (4, 5) . In a phase III trial comparing oral topotecan with best supportive care (BSC), the MST was 25.9 weeks for patients receiving topotecan and 13.9 weeks for those receiving BSC (hazard ratio [HR], 0.64; 95% CI, 0.45-0.90; P = 0.0104) (6) . Thus, second-line chemotherapy for relapsed SCLC was effective. However, this study included only patients with TFI ≥ 45 days and selectable second-line drugs were limited. Topotecan is currently the only drug approved for the treatment of relapsed SCLC patients in the USA (6) (7) (8) .
To date, there has been no phase III trial conducted for patients with refractory-relapsed SCLC. A phase II trial and subgroup analysis of a phase III trial showed that second-line chemotherapy for refractory-relapsed SCLC had an overall response rate (ORR) of 0-50%, median progression-free survival (PFS) of 1.5-3.5 months and MST of 4.7-10.3 months (9) (10) (11) (12) (13) (14) . However, only a small number of poor-risk patients were included in previous reports. It is unclear whether second-line chemotherapy for poor-risk patients with refractory-relapsed SCLC is effective. Therefore, we retrospectively analyzed the efficacy of second-line chemotherapy for poor-risk patients with refractory-relapsed SCLC.
Patients and methods

Patients
We retrospectively examined the medical record data of 459 consecutive SCLC patients who were treated with first-line treatment between September 2002 and December 2014 at Shizuoka Cancer Center. The recruitment criteria of this study were as follows: (i) histological or cytological confirmation of SCLC; (ii) refractory relapse after one previous chemoradiotherapy or chemotherapy regimens; (iii) treatment with second-line chemotherapy and (iv) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥ 2 at the time of administration of second-line chemotherapy.
In this study, we defined TFI as the period from the date of completion of first-line treatment to the first relapse. Also, we defined refractory relapse as TFI < 90 days, according to the definition in several previous trials (11) (12) (13) . Poor-risk patients were defined as ECOG PS ≥ 2.
Evaluation and statistical analysis
We evaluated tumor response to chemotherapy according to the Response Evaluation Criteria in Solid Tumors by performing computed tomography of the chest and abdomen, magnetic resonance imaging of the head, and bone scintigraphy or positron emission tomography-computed tomography (15) . Clinical evaluation of PFS and overall survival (OS) after the start of the second-line chemotherapy was conducted by the Kaplan-Meier method to assess the time of recurrence or death. We assessed toxicity by National Cancer Institute Common Toxicity Criteria, version 4.0. All statistical analyses were performed using JMP version 9.0 (SAS Institute Inc., Cary, NC). Our study was approved by the Institutional Review Board.
Results
Patient characteristics
Between September 2002 and December 2014, 459 SCLC patients were treated with first-line treatment and 220 patients (48%) were diagnosed with refractory-relapsed SCLC. Among them, 54 patients (12%) had an ECOG PS of 2 or more at the time of second-line treatment. Finally, 23 poor-risk patients with refractory-relapsed SCLC were enrolled in this study.
Patient characteristics are shown in Table 1 . Median age was 71 (range 57-83) years. Seventeen patients were male (74%). All patients with the exception of one patient had extensive disease at diagnosis (96%). Thirteen patients had an ECOG PS of 2 or more at first-line treatment. ORR after first-line treatment was 74% and median TFI was 26 days. In regard to second-line chemotherapy, 15 patients (65%) were treated with amrubicin and three patients (13%) were treated with irinotecan. Almost all patients (87%) had an ECOG PS of 2 at the time of second-line chemotherapy.
Efficacy
Among patients treated with second-line chemotherapy, five had a partial response and ORR was 22% (Table 2) . Median PFS (95% CI) was 2.2 months (1.6-3.2 months) and MST (95%CI) was 3.7 months (2.4-5.2 months) ( Figure 1A and 1B) .
Among patients treated with amrubicin, two had a partial response and ORR was 13% (Table 2) . Median PFS (95%CI) was 2.2 months (1.3-3.4 months) and MST (95%CI) was 3.9 months (2.2-6.6 months) ( Fig. 2A and B) . 
Safety
Toxicity was evaluated in all patients treated with second-line chemotherapy and those treated with amrubicin ( Table 3 ). The most common grade 3 or worse adverse events in patients treated with second-line chemotherapy were hematologic toxicities, including leukopenia (66%), neutropenia (69%), thrombocytopenia (9%) and anemia (22%). Febrile neutropenia was observed in two patients (9%). Grade 3 or worse non-hematologic toxicities were pneumonitis in four patients, appetite loss in two patients, infection in one patient, arthralgia in one patient, myalgia in one patient, sepsis in one patient and hypoxia in one patient. There was no treatmentrelated death.
Among patients treated with amrubicin, grade 3 or worse leukopenia and neutropenia were observed in 11 patients (74%). Febrile neutropenia was observed in one patient (7%). Grade 3 or worse non-hematologic toxicities were pneumonitis in three patients, appetite loss in two patients, sepsis in one patient and hypoxia in one patient.
Discussion
In this study, we retrospectively assessed the efficacy of second-line chemotherapy for poor-risk patients with refractory-relapsed SCLC. ORR was 22%, median PFS was 2.2 months and MST was 3.7 months for patients treated with second-line chemotherapy in our study.
There has been no phase III trial comparing second-line chemotherapy with BSC for patients with refractory-relapsed SCLC. However, previous reports showed moderate efficacy of second-line chemotherapy for patients with refractory-relapsed SCLC. The ORR was 0-50%, median PFS was 1.5-3.5 months and MST was 4.7-10.3 months (9) (10) (11) (12) (13) (14) . Given that the prognosis of relapsed SCLC patients was 2-4 months without treatment, second-line treatment for patients with refractory-relapsed SCLC might be reasonable (3). And PS 0-2 patients with refractory-relapsed SCLC were recommended for second-line treatment in NCCN guideline. However, poor-risk patients with refractory-relapsed SCLC were included only 3-13 patients in those previous study. In addition, there are no studies of second-line chemotherapy for poor-risk patients with refractory-relapsed SCLC. It is unclear whether second-line chemotherapy for poor-risk patients with refractory-relapsed SCLC is effective. Considering our results with the prognosis of patients who receive BSC, second-line chemotherapy might not be appropriate for poor-risk patients with refractory-relapsed SCLC.
Amrubicin is a synthetic 9-amino-anthracycline. The MST of patients with refractory-relapsed SCLC who received amrubicin was 5.3-10.3 months in previous studies (9) (10) (11) (12) (13) . In a subgroup analysis of a phase III trial comparing amrubicin with topotecan, OS of refractory-relapsed patients was significantly longer in the amrubicin group than in the topotecan group (MST 6.2 months vs 5.7 months; HR, 0.766; P = 0.047) (13) . Based on the previous reports, amrubicin is usually administered as second-line chemotherapy for patients with refractory-relapsed SCLC in Japan and is the most commonly used drug in our hospital. However, the efficacy of amrubicin was poor and was comparable with all regimens in our study. Compared with the results of a phase II trial involving PS 0-1 patients with refractory-relapsed SCLC, amrubicin-related hematological toxicities were less frequent. But amrubicin-related non-hematological toxicities, including pneumonitis, were more frequent in our study (12) . The median number of treatment cycles was four in the phase II study and two in our study. The difference of treatment cycles might have influenced the results of hematological toxicities.
Our study had several limitations. First, the sample size was too small and the timing of response assessment was decided by each physician, which might have resulted in variance of ORR and PFS. Second, we did not assess patients' quality of life (QOL). Although the MST of poor-risk patients with refractory-relapsed SCLC was comparable with that of BSC, there was a possibility that the QOL of patients treated with second-line chemotherapy was improving. We think that the assessment of QOL is necessary in the future. Finally, it was a most important limitation that there was no control group in our study. When setting the BSC group as the control group, there were several problems. First, it was difficult to decide the start of BSC. If the date of progression of first-line treatment is defined as the start of BSC, the start date of second-line treatment differs between the second-line chemotherapy group and the BSC group. Second, the BSC patients included many patients that were not suitable for second-line chemotherapy and the patients characteristics differed in both group. Patients who were suitable for second-line chemotherapy and did not want any treatment were only four patients.
In conclusion, second-line chemotherapy might have poor efficacy to poor-risk patients with refractory-relapsed SCLC. The results suggest that second-line chemotherapy, including amrubicin, might not be appropriate for poor-risk patients with refractoryrelapsed SCLC. (7) 1 (7) 0 (0) Vomiting 6 (26) 1 (4) 0 (0) 2 (13) 1 (7) 0 (0) Diarrhea 1 (4) 3 (13) 0 (0) 1 (7) 1 ( 
